KBC Master Fund Business Core Satellite Dynamic (0P00019Y7A)

Overview

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of pioneering therapeutics aimed at fulfilling the unmet medical needs in viral and liver diseases. Incorporated in 2018 and based in South San Francisco, California, Aligos Therapeutics has carved a niche for itself by focusing on the discovery and development of targeted treatments that could potentially offer new hope for patients suffering from chronic conditions such as non-alcoholic steatohepatitis (NASH), chronic hepatitis B (CHB), and coronavirus. With a strategic approach to research and development, coupled with collaborations with eminent institutions and companies, Aligos Therapeutics is poised at the forefront of combating these serious health challenges.

Products and Services

• ALG-055009

A cutting-edge small molecule THR-ß agonist that is currently in a Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). This drug candidate epitomizes Aligos Therapeutics' commitment to addressing the rapidly increasing incidence of NASH, a severe liver disease with significant unmet medical needs.

• ALG-000184

A capsid assembly modulator that has successfully completed a Phase 1b clinical trial for treating chronic hepatitis B (CHB). ALG-000184 represents a novel approach to managing CHB, offering potential improvements over existing therapies by targeting the virus's capability to replicate.

• ALG-125755

An innovative siRNA drug candidate undergoing a Phase I clinical trial aimed at treating chronic hepatitis B (CHB). By utilizing siRNA technology, ALG-125755 seeks to silence the viral RNA, thereby reducing the virus's ability to replicate and cause liver damage.

• ALG-097558

Currently in a Phase 2 clinical trial, ALG-097558 is being developed for the treatment of coronavirus. This investigational drug highlights Aligos Therapeutics' agile response to global health crises and its role in advancing treatments for emerging viral diseases.

Furthermore, Aligos Therapeutics has established a robust alliance and collaboration network to enhance its research, development, and commercial capabilities. These include a license and research collaboration agreement with Merck for oligonucleotides targeting NASH; a license agreement with Emory University for hepatitis B virus capsid assembly modulator technology; a licensing deal with Luxna Biotech Co., Ltd. for oligonucleotides targeting the hepatitis B virus genome; and a research, licensing, and commercialization agreement with Katholieke Universiteit Leuven for developing coronavirus protease inhibitors. A clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. also forms a crucial part of its strategic partnerships.